Royalty Pharma plc: Royalty Pharma announces update on Novartis' Phase 3 topline results for pelacarsen
Royalty Pharma (RPRX) updated on Novartis' Phase 3 trial for pelacarsen, which failed to meet its primary endpoint. Despite this, RPRX expects to recoup its $500M investment and earn a modest return. The company reiterated its 2030 Portfolio Receipts target of $4.7B+.
How this was made
The 30-second read
Why it matters
The failure reduces expected cash flows from pelacarsen royalties, but the Spinraza component remains intact, partially mitigating impact.
Market read
The trial miss may trigger a sell-off in RPRX and affect other royalty-focused biotech funds.
What to watch
Potential for future licensing or alternative indications for pelacarsen could revive royalty value.
Background
Royalty Pharma funds biotech royalties and announced a $500M funding deal with Ionis, linking returns to pelacarsen and Spinraza outcomes.
Ticker impact
Royalty Pharma disclosed that Novartis' Phase 3 pelacarsen trial failed to meet its primary endpoint.
Downward pressure on RPRX price in the short term.
Royalty Pharma's return assumptions hinge on pelacarsen royalties; the miss removes expected milestone payments and reduces future cash flows.
Market effects
Biotech royalty investors may reassess exposure to development-stage assets.
Limited to US-listed royalty funds and biotech sector.
Highlights risk of antisense therapies targeting Lp(a) across markets.
Counterpoint
Spinraza royalties may offset the pelacarsen loss, supporting a longer-term view.
Key entities
- companyRoyalty Pharma plc
US-listed royalty fund (Nasdaq: RPRX).
- companyNovartis
Pharma partner conducting the pelacarsen trial.
- companyIonis Pharmaceuticals
Partner in the royalty funding agreement.
